|Positive IHC detected in||human breast cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Immunohistochemistry (IHC)||IHC : 1:5000-1:15000|
|Sample-dependent, check data in validation data gallery|
66300-1-Ig targets PR in IHC, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||PR fusion protein Ag22992|
|Full Name||progesterone receptor|
|Calculated molecular weight||933 aa, 99 kDa|
|GenBank accession number||NM_000926|
|Gene ID (NCBI)||5241|
|Purification Method||Protein A purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
PGR, also named as NR3C3 and PR, belongs to the nuclear hormone receptor family and NR3 subfamily. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation. The ER and PR status has been used as a predictor of breast carcinoma responsiveness to endocrine therapy and as a prognostic indicator for early recurrence.
Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy
Mol Med Rep
HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.